Life Sciences companies are taking a front-row seat in the current wave of intelligent digitalization. Digital health trackers and intelligent sensors initiatives for the Life Sciences industry face unique challenges due to the regulatory landscape. Life Sciences companies ideally prefer digital technology partners that provide end-to-end transformation services and offerings complemented by their ability to offer unique solutions tailored to their requirements.
Visionet is a partner of choice for top Life Sciences and Healthcare companies. We have enabled our clients’ digital transformation with technology accelerators in AI, medical imaging, NLP, data platform modernization, and AI-based digital biomarker processing. Our next-generation AI-first trials and services enable our clients to accelerate time-to-market, improve patient engagement, optimize the cost of clinical trials, and modernize their research pipeline.
Our clients prefer Visionet due to our multifaceted industry experience and ability to provide end-to-end support in all stages of their journey. We help them reduce siloed thinking during the transformation of business functions.
Visionet partners with Life Sciences companies to develop novel digital clinical endpoints by harmonizing third-party sensor and device data into a standard schema. This schema helps synchronize sensor data with other physicians and patient-reported outcomes. Visionet’s Intelligent Sensor Data Platform facilitates novel digital endpoint validation against the standard of care methods. Our platform provides endpoint data in formats compatible with CDISC standards. Our experience with novel endpoint engagements involves multiple therapeutic areas, including neurology, oncology, cardiovascular or metabolic diseases, dermatology, hematology, and immunology. Our wide range of expertise includes the technology frameworks for the following sensors and devices:
Our Pharmacovigilance AI technology and PV consulting team have potential risks the expertise in providing solutions related to ICSR reports, AE (Adverse Event) mention detection, AE MEDRA coding, causality detection, and signal generation from AE mentions in data sources such as regulatory reports, clinical trials, spontaneous ADR reports, and literature reports.
Visionet leverages cutting-edge NLP solutions for optimizing adverse event reporting by harnessing the power of advanced AI algorithms, including GPT-4, Bio-BERT, and knowledge graphs. Our revolutionary technology can rapidly detect potential adverse drug reactions, anticipate drug interactions and causality, and pinpoint patterns and trends that may indicate safety concerns. With our NLP, LLMs, and knowledge graph-based pharmacovigilance, you can reduce potential risks while improving patient outcomes and driving drug development success.
Visionet's AI-DTx platform provides artificial intelligence algorithms and pipelines to create personalized treatment plans, track patient progress, and provide real-time feedback to optimize outcomes. Our AI enables digital therapeutics design and validation that can revolutionize how medical professionals and pharma approach chronic disease management, mental health care, and condition management for cardiovascular and neurological diseases. The platform provides mobile application backend and frontend templates for DTx strategy, data plugins for phone sensors and wearable Bluetooth sensors, along with edge and cloud AI libraries to implement algorithms.
Unlike traditional biomarkers, which rely on static measurements, AI-driven digital biomarkers continuously monitor a patient's unique data streams, enabling early disease detection, more precise diagnoses, and support tailored treatment plans. With AI for digital biomarkers, healthcare providers can improve patient outcomes and revolutionize disease prevention and management. Our AI-based biomarker processing framework supports numerous devices, wearable sensors, and imaging modalities. This results in novel biomarkers derived through AI by mixing and matching the data from existing measurement methods.
Current trends are driving Life Sciences companies toward the AI transformation of the molecule to market processes. Integrating state-of-the-art AI technology into research and development processes can optimize drug discovery, accelerate time-to-market, and improve patient outcomes. Visionet AI COE offering (consulting and engineering) supports the AI enablement roadmap for Life Sciences companies. The goal of a Pharma AI COE as a central IT initiative is to enable functional business users of AI (“Citizen Data Scientists”) with the AI transformation of their current business processes. Visionet’s team also initiates ongoing support for horizontal enablement activities like MLOPs support, adoption and literacy of AI, and external partnerships with Life Sciences research groups in academia and industry for AI-driven research and drug development. We also support their journey towards AI ethics, health equity, fairness, security, and explainability and assist with regulatory validation and documentation.
Single platform to integrate dozens of wearable sensors and device data clouds in a GXP environment. It harmonizes sensor data in a standardized structure for the extraction of endpoint measures through the use of Signal Processing and AI.
Learn More Our Solutions
A leading pharmaceutical company faced challenges in streamlining data from multiple sensor devices provided by different manufacturers to measure drug efficacy. Visionet proposed an intelligent sensor data platform that standardized analytical schema, provided an ingestion layer for variety of sensors and an AI framework.
Download case study
Helping you deliver the real difference.
